1079 Phospho-proteomic profiling reveals distinct signaling pathways by first and third generation EGFR inhibitors in human keratinocytes: Implications for adverse dermatologic reactions

The epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase and a major regulator of cellular proliferation, differentiation, and survival. Aberrant EGFR signaling is a major driver of both cutaneous and non-cutaneous cancers and has also been implicated in conditions such as psoriasis and eczema. While EGFR inhibitors are commonly used to treat several malignancies, they notoriously result in adverse dermatologic effects, including papulopustular and acneiform eruptions, pruritus, paronychia, xerosis, and mucositis.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Pharmacology and Drug Development Source Type: research